Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Altogether, this validates our focus on growing the best strains to deliver the best consumer experience we want for our customers |
| However, over the last 12 months, the organization has made remarkable progress as we have executed our strategic priorities to strengthen the balance sheet, resize the business, and position the company for long-term growth and profitability |
| Irwin has been great from the standpoint of working together and putting this -- the businesses and really the synergies that are going to come through |
| So, we're really, really pleased with how that is being accepted by the marketplace |
| I also see an amazing area when you take a look at the bulk and combined with this incredible growth |
| And so those orphaned and stranded strains they became excellent opportunities for us to put out in the market |
| And as a combined company, we will be better positioned to drive profitable growth, capitalize on this complementary portfolios of an industry leading with these high-growth brands |
| Taken together, these efforts not only resulted in a higher quality cannabis experience for our customers, it also drove our margins higher |
| Tilray has been an excellent partner over the last year |
| I'm proud we have accomplished over the past year in an industry that is going through a significant change |
| We also drove significant impactful improvements in our cost structure by pursuing aggressive cost-cutting strategy, which has reduced our SG&A footprint by almost $17 million on an annualized basis |
| Next, we delivered improvements in our working capital management as we have reduced our working capital by $135 million versus a year ago |
| The outcome of the process and cultural changes have resulted in our cash conversion cycle improving by over 100 days, which is truly remarkable and reflective of the efforts of the entire finance and operation teams |
| Given these successes, HEXO has delivered positive cash flow from operations for two consecutive quarters |
| This builds on the strategic partnership we established last year and reflects the significant progress we've been able to make both financially and operational since that time |
| And as I mentioned earlier, we were successful in achieving positive cash flow from operations for the second consecutive quarter and we delivered a $78 million improvement in operating cash flows versus Q3 '23 -- for Q3 '22, reflecting an aggressive cost-cutting strategy as well as balance sheet improvements we have achieved over the past year |
| Next, we saw strong momentum in our in-house developed TnT strains, which now represent over 37.5% of all flower sales |
| Our gross margin increased 10% versus the prior quarter to 43%, confirming that our strategy to focus on our most profitable brands is delivering results |
| This demonstrates the success of our inside our Core Walls program |
| This marked our four-consecutive quarter of sequential improvement in SG&A spending |
| It's really good |
| We capitalized on a high growth potential in the pre-roll segment and we expanded our capacity in our popular Straight Edge Pre-Rolls, including accelerating the Redecan ready's product to include some of the TnT series and expanding our original Stash brands |
| This is an incredible growth since the introduction of these TnT strains to the market just about four months ago at the end of Q1 |
| Now we've got Valico, Automic Hour Hays and Ghost Gelato that are all gaining significant traction |
| With bulk sales more than doubling from second quarter, we effectively leverage the Redecan master growers’ program as a point of differentiation for HEXO |
| This expansion resulted in a fourfold increase in the Redecan Pre-Roll capacity and enables us now to meet the growing consumer demand across Canada |
| Our margins are now about 10% higher than they were a year ago |
| This represents an improvement of $13.2 million versus the year ago quarter |
| Looking ahead, we're very excited about closing the transaction with Tilray Brands, which is on track to be completed by the end of the month |
| Looking at our Q3 financial results, expense controls continue to remain our top priority, and I am pleased to share that SG&A spending improved by $2.5 million or 20% compared to the second quarter after adjusting for the annual Health candidates |
| Statement |
|---|
| Growth at Q3 '22, our sales are down 53% due to increased competition, fee rationalization of lower-margin products, soft performance in key markets, Ontario, Alberta, Quebec, and the removal of product portfolios for divested benefits business, along with trust beverage |
| In terms of revenue, net sales decreased 11% quarter-over-quarter to $21.6 million |
| This decline is attributable to lower adult new sales in Alberta, reduced emphasis in Saskatchewan and in Manitoba, supply chain -- I'm sorry, short-term supply issues, and delisted products in Quebec |
| At that time, HEXO faced significant challenges, including a debt leverage, liquidity constraints, excessive inventory, excessive overhead costs, acquisitions were not integrated into the parent organization |
| In short, the company was grappling with a host of financials and operational issues |
| In addition to the Tilray announcement, we also had a number of notable operational and product developments even as we continue to face a challenging competitive landscape and an ever-increasing uncertainty in the macro environment |
| Due to the transaction, we incurred a 74 CGU impairment charge to reflect Tilray's purchase price combined with an acquisition fee of $20 million, resulting in a net income loss of $115 million for the period |
| And so, the repeat sales on the older brands are starting to slow down, while the new strains are starting to come on board |
| Excluding the $2.5 million in annual Health Canada fees, we recognized an adjusted EBITDA loss of $1.4 million |
| It was a tough year |
| But just given that there's been double-digit sequential declines for the last couple of quarters in your adult use |
| In short, we do not grow just to grow |
| Inventory alone was down over $100 million as our S&OP processes were redefined and still in public philosophy, every cannabis plant is not a good plant |
Please consider a small donation if you think this website provides you with relevant information